THERAMetrics holding AG (SIX: TMX) reports the scientific publication of its bio-mathematical Search & Match technology for Drug Rescuing and Repurposing ( DRR-2.0 )

Stans, Switzerland, January 27, 2014 - Therametrics Holding AG announces the launch of the new platform DRR-2.0 and reports the scientific publication of the paper "Graph theory enables drug repurposing – How a mathematical model can drive the discovery of hidden Mechanisms of Action", describing the bio-mathematical model of its Search & Match technology.

Thanks to the successful outcome of the study conducted by Therametrics' scientists in collaboration with Mr. Ruggero Gramatica and the department of Mathematics at University King's College London, the research titled "Graph theory enables drug repurposing – How a mathematical model can drive the discovery of hidden Mechanisms of Action", was published by PLoS ONE, the largest scientific peer-reviewed journal in the world. Such a study about an innovative drug screening methodology sets the foundations for the deployment of an advanced in-silico bio-mathematical platform for the discovery of Drug Rescuing and Repurposing (DRR-2.0) methodology whose rationale is based on new "repositioned / repurposed" uses of drugs against diseases.
The article is available without cost at the following link: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0084912 

Raffaele Petrone, Chairman of Therametrics, commented: "thanks to the extraordinary ability of this platform to generate several patho-physiology leads showing hidden or emerging patterns of unknown mechanisms of action, the Company is pioneering a new way of exploiting these capabilities offering integrated services, from drug discovery to clinical research organizations. Furthermore, the powerful mathematical model for discovery underlying this research is being further studied and developed in other cross-disciplinary fields by Mr. Ruggero Gramatica and colleagues at Stanford University independent of Therametrics' Search & Match platform.
We foresee the platform becoming available in Q1-2014 to the Pharma Industry."

About THERAMetrics THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland).

For further information please contact THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] www.therametrics.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.